Rifampicin (RFP)の免疫抑制作用について

概要

論文の詳細を見る
Rifampicin (RFP) is one of the active antibiotics for the treatment of pulmonary tuberculosis, and at the same time, very interesting agent for biochemical research including RNA synthesis, immunosuppressive effect, antitumor effect and anti-allergic effect, and etc. Although some data show that RFP has immunosuppressive effect on hum o ral and cellular immune reactions in vivo and in vitro, the mechanism of this action of RFP, especially problems about target cell of RFP, has remained obscure. It is most important to study whether the immunosuppressive effect of RFP is advantageous or not in the treatment of patients and how therapeutic doses of RFP effect on immunological status in patients. From the above stand points, tuberculin hypersensitivity, lymphocyte counts, T lymphocyte counts and serum γ-globulin were examined on 20 patients treated with therapeutic dose of RFP and the results were compared with the controls treated with other antituberculous drugs. The results show that: (1) Significant decrease of tuberculin hypersensitivity and T lymphocyte counts were observed at 2 and 4 weeks after administration of RFP in the most of cases but this decrease was recovered after 8 weeks. (2) Lymphocyte counts and serum γ-globulin were not affected. From the above results, it is suggested that T-lymphocyte may be one of the target cell of RFP but the interference of RFP on immunological status of patients was transient and reversible.
一般社団法人日本結核病学会の論文

Rifampicin (RFP)の免疫抑制作用について

スポンサーリンク

概要

著者

関連論文

スポンサーリンク